Skip to main content

Table 1 Characteristics of studies selected in the meta-analysis

From: The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis

Study Year NOS Journal Region Total number TET2m Median age Detecting method Data type Therapy regimen Cohort type
Wahab 2009 7 Blood America 91 11 65 Unknown Calculated from K-M curves Unknown AML
Nibourel 2010 6 Blood France 111 19 43 Direct sequencing Calculated from K-M curves Anthracycline-cytosine arabinoside induction treatment followed by HDAC consolidation or allo-HSCT AML
Metzeler 2011 9 Journal of Clinical Oncology America 418 95 > 60 Direct sequencing Calculated from K-M curves Standard intensive therapy CN-AML
Kosmider 2011 7 Haematologica France 247 49 66 Direct sequencing Unitivariate or calculated from K-M curves Intensive chemotherapy with anthracycline-cytarabine s-AML
Chou 2011 7 Blood China 486 64 51.5 Unknown Multivariate and calculated from K-M curves Standard intensive therapy or palliativecare or low-dose chemotherapy AML
Patel 2012 8 The New England Journal of Medicine America 391 33 < 60 Direct sequencing Calculated from K-M curves Induction therapy with high or standard dose of DNR AML
Weissmann 2012 7 Leukemia Germany 318 87 66.4 Next-generation sequencing Calculated from K-M curves Unknown AML
Gaidzik 2012 8 Journal of Clinical Oncology Germany 783 60 < 60 Direct sequencing Calculated from K-M curves Double induction therapy AML
Renneville 2014 6 Oncotarget France 139 19 62 Direct sequencing Univariate Standard front-line chemotherapy with or without low-dose gemtuzumab ozogamicin CN-AML
Damm 2014 8 Genes Chromosomes and Cancer France and Germany 215 13 < 60 Direct sequencing multivariate Intensive double induction and consolidation therapy CN-AML
Tian 2014 7 International Journal of Hematology Asia 373 60 45 Direct sequencing Calculated from K-M curves Standard induction therapy followed by consolidation of HDAC or allo-HSCT CN-AML
S.Ohgami 2015 7 Modern Pathology America 93 6 55 Next-generation sequencing Muitivariate Standard induction therapy with cytarabine and danorubicin or idarubicin AML
Ahn 2015 9 Haematologica Multiple region 407 54 52 Direct sequencing Muitivariate Standard induction therapy CN-AML
Kao 2015 8 Oncotarget China 98 18 55 Direct sequencing Calculated from K-M curves Standard intensive therapy with daunomycin and cytarabine AML with MLL-PTD
Cher 2016 8 Blood Cancer Journal China 96 8 41 Next-generation sequencing Multivariate and univariate Induction chemotherapy comprising cytarabine and daunorubicin with consolidation therapy comprising HDAC or allo-HSCT CBF-AML
Lin 2016 9 Cancer Medicine China 112 12 42.6 Next-generation sequencing Multivariate Standard therapy with or without allo-HSCT AML
  1. Abbreviations: NOS the Newcastle-Ottawa-Scale, TET2, tet oncogene family member 2, m mutation, HDAC high-dose cytarabine, allo-HSCT allo hematopoietic stem cell transplantation, CN-AML cytogenetically normal acute myeloid leukemia, s-AML secondary acute myeloid leukemia, MLL-PTD partial tandem duplication of mixed-lineage leukemia gene, CBF-AML core-binding factor acute myeloid leukemia